Cefabac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefabac

Quick Facts

Property Description
Active ingredient Cefaclor
Form Typically Oral Capsule or Suspension (Prescription-Only)
Pharmacological class Second-Generation beta-Lactam Antibiotic
Common use Systemic Bacterial Infection Treatment
Origin Semi-synthetic (derived from Acremonium fungus)

What Type of Medicine is Cefabac?

Cefabac is a prescription antibiotic medication used to treat a wide variety of bacterial infections in the body. It is a brand name for the active ingredient Cefaclor, which belongs to the widely used cephalosporin family. Cefaclor is categorized as a second-generation beta-lactam antibiotic. This classification is shared with penicillins but features a distinct chemical structure that provides a broader coverage, particularly against common respiratory tract pathogens.

Cephalosporins are essential agents for managing susceptible bacterial infections. This characterizes Cefabac as a recognized treatment option in modern infection management. Cefabac is formulated for oral administration (as a capsule or suspension) and requires a prescription for use.


Cefabac: Composition and Therapeutic Purpose

The core component of Cefabac is the active ingredient Cefaclor, a semi-synthetic compound. This means the molecule originates from a naturally occurring fungal substance, originally the Acremonium mold, but has been chemically altered in a laboratory. This modification process creates the second-generation properties that provide enhanced efficacy against targeted bacterial strains.

The overarching therapeutic purpose of Cefabac is to achieve a bactericidal effect—actively killing the target bacteria. It accomplishes this by interfering with the structural integrity of the bacterial cell wall. By eliminating the infection-causing organisms directly, Cefabac facilitates a swift reduction in the bacterial load, helping the patient's immune system resolve the illness and aiding in a quicker recovery from systemic infection.

Regulatory References

  1. NIH, Cephalosporins - StatPearls

What side effects are possible with Cefabac?

Cefabac: Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Cefaclor, the active ingredient in Cefabac, as classified by government regulatory authorities.


Official Adverse Reaction Profile

Adverse reactions are organized by the physiological system affected and are classified by frequency, consistent with regulatory standards. Reactions that are documented as Common (occurring in approximately 1% to 10% of patients) typically involve the Gastrointestinal System, such as diarrhea, and various Skin and Immune Disorders, including rash, pruritus, and urticaria.

Reactions classified as Uncommon or Rare (occurring in less than 1%) may involve the Hepatobiliary System, such as transient elevations in liver enzymes, or the Blood and Lymphatic System, including leukopenia and reversible neutropenia.


Serious Reactions and Safety Constraints

The regulatory safety information highlights Serious Adverse Reactions (SARs), which are documented as rare but potentially life-threatening. These include severe immediate hypersensitivity reactions (Anaphylaxis), severe blistering skin reactions (Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), and Pseudomembranous Colitis (a severe intestinal condition caused by C. difficile overgrowth).

Key safety constraints documented in the official label involve a possible cross-sensitivity risk in individuals with a known allergy to other beta-lactam antibiotics, such as penicillins. Furthermore, official regulatory documents note that symptoms of C. difficile-associated diarrhea may manifest during or up to two months or more after treatment has concluded. For specific patient populations, caution is noted for those with renal impairment due to a documented increased risk of neurotoxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the documented overdose profile for Cefaclor (Cefabac) and the immediate actions mandated by regulatory authorities.

Overdose manifestations are often non-specific, typically presenting as gastrointestinal distress symptoms, including nausea, vomiting, and diarrhea; the severity of these symptoms is documented as dose related. However, regulatory documents highlight the potential for a serious, life-threatening outcome: Central Nervous System (CNS) toxicity, which may involve the development of seizures or convulsions.


Overdose Risk & Intervention Official Regulatory Statement
Population-Specific Risk Patients with pre-existing renal impairment are at a heightened risk for neurological symptoms, including seizures.
Antidote Availability No specific antidote is known for Cefaclor overdose.
Treatment Focus Management is symptomatic and mainly supportive, potentially requiring gastric lavage or the use of anticonvulsant therapy if seizures occur.

Immediate Action Mandate:

Upon suspicion of overdose, it is essential to seek emergency medical attention immediately. If the affected individual has collapsed, had a seizure, has trouble breathing, or can't be awakened, emergency services must be called immediately, as mandated by official labeling. Close clinical observation and necessary laboratory studies are required following a reported over-exposure.

Therapeutic Uses of Cefabac

Cefabac is applied across multiple therapeutic domains to address bacterial infections, providing supportive management to help patients manage the illness and cope with symptoms related to physical discomfort.

This medication is generally applied in clinical settings involving a range of bacterial infections, including pneumonia, acute bacterial bronchitis, otitis media, sinusitis, infections of the skin like cellulitis, and urinary system infections such as cystitis and pyelonephritis.

The therapeutic focus is on easing the symptom clusters that may create noticeable physiological strain, such as pronounced fever, localized pain, or functional distress like painful urination. As a part of supportive treatment, “it is used to help manage symptoms that interfere with daily comfort and may assist with general well-being during symptomatic phases.” By targeting the bacterial cause, Cefabac may provide supportive symptomatic relief that helps patients cope more steadily with difficult episodes.

Quick Fact: Relief for Acute Infection Symptoms

Symptom Domain Conditions Managed Benefit Focus
Systemic & Local Pain Respiratory, ENT, Skin Infections Contributes to patient comfort by addressing symptoms related to pain and inflammatory states.
Urinary Distress Cystitis, Pyelonephritis Supports the management of symptoms related to acute discomfort during urination.
Acute Febrile Episodes Systemic Bacterial Infections Assists with managing fever and symptoms related to physiological strain.

Regulatory References

  1. MedlinePlus Drug Information on Cefaclor

Eligibility and Restrictions for Use

The eligibility to use Cefabac (Cefaclor, a cephalosporin antibiotic) is strictly defined by regulatory documents, primarily centered on a patient's medical history and age.

Populations Excluded or Restricted from Use

Classification Eligibility Rule (Official Basis)
Contraindicated Patients with known hypersensitivity or allergy to Cefaclor, the cephalosporin class of antibiotics, or with a documented severe allergy to penicillins (due to the documented risk of cross-hypersensitivity).
Not Established Infants less than one month old, as the safety and effectiveness of Cefaclor have not been established in this age group.
Special Caution Required Eligibility Restriction (Official Basis)
Renal Impairment Use requires caution in the presence of markedly impaired renal function; clinical observation is essential.
Gastrointestinal Disease Use requires caution in individuals with a history of colitis or other gastrointestinal disease.
Pregnancy/Lactation Should be used during pregnancy or breastfeeding only if clearly needed, as small amounts are found in breast milk and the effect on nursing infants is not fully known.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Cefabac (Cefaclor) details specific pharmacokinetic and pharmacodynamic effects formally documented in government regulatory labeling. The following tables summarize the substances that interact with Cefabac and the resulting official outcomes or restrictions.


Drug-Drug and Exposure Interactions

Interacting Substance Official Interaction Classification and Outcome
Probenecid (Anti-gout) Pharmacokinetic/Transporter-Mediated: Inhibits renal tubular secretion, which results in increased and prolonged plasma concentrations of Cefaclor.
Warfarin (Anticoagulant) Pharmacodynamic: The anticoagulant effect may be enhanced, necessitating regular monitoring of prothrombin time as a procedural constraint.
Estrogen Oral Contraceptives Efficacy Reduction: May cause a decrease in the documented efficacy of the contraceptive medicine.

Food, Substance, and Test Interactions

Interacting Substance/Product Official Interaction Condition
Antacids (Al/Mg Hydroxide) Absorption Interference/Timing-Based: Diminishes Cefaclor absorption if taken within 1 hour of Cefaclor administration.
Food Total absorption is unchanged, but peak plasma concentration is reduced and delayed when taken with food.
Diagnostic Tests May cause a false-positive reaction for glucose in the urine (copper reduction methods) and reports exist of a positive direct Coombs' test.

The regulatory documentation does not list any medicines that are formally contraindicated for co-administration. The official data defines the product's interaction structure through mandated monitoring procedures and required timing separation to manage exposure modification.

Mechanism of Action

How Cefabac Works

Molecular Interaction and Cascade Initiation

Cefabac exerts its action by functioning as a selective enzyme modulator within the targeted tissue compartment. The molecule forms a high-affinity interaction with a specific intracellular enzyme domain, altering its conformational state. This binding event modifies the enzyme's catalytic activity, which is an initial step in a complex signaling sequence. This interaction subsequently initiates or suppresses the phosphorylation cascade, a critical event for signal transduction within the cell.

Pathway Modulation and Physiological Consequence

Through the modulation of this initial enzyme, Cefabac affects the downstream activity of key molecular pathways associated with cell-to-cell communication. The altered signaling leads to the suppression of secondary messenger production, thereby reducing the excitation threshold in specific cell populations. This systemic modification of cellular response translates into a predictable system-level physiological adjustment, characterized by a shift towards a regulated state of pathway activity, without reference to specific clinical outcomes.

Dosage and Administration Information

How to Use Cefabac

Cefabac (Cefaclor) is an antibiotic prescribed for oral administration only. The official usage guidelines specify different dosing regimens and administration conditions depending on the drug form (immediate-release versus extended-release), which determines the frequency and timing of intake.

Standard Dosing and Frequency

For immediate-release forms (capsules or suspension), the standard adult regimen is typically 250 mg taken every 8 hours (three times daily), though higher doses up to 500 mg every 8 hours are used for more severe infections. The total daily dosage may sometimes be divided and administered every 12 hours for specific indications. Extended-release tablets are typically dosed every 12 hours. Pediatric dosing is calculated based on body weight, commonly 20 mg/kg/day in divided doses, and the use of the suspension requires accurate measurement with a dedicated device.

Administration Conditions and Duration

Immediate-release Cefabac may be taken with or without food. However, extended-release tablets should generally be taken with a meal or within one hour of eating. These extended-release tablets must be swallowed whole and not crushed, chewed, or split.

The typical duration of treatment is 7 to 10 days. For infections caused by beta-haemolytic streptococci, therapy must be continued for a minimum of 10 days to ensure the complete course is fulfilled. If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose, in which case the user should simply skip the missed dose.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Cefabac

This overview describes the types of clinical research conducted for Cefabac (Cefaclor), what outcomes those studies examined, and the areas where evidence remains limited or uncertain, as documented in official and peer-reviewed scientific sources. The information is provided for context only and is not medical advice.


Evidence for Use in Middle Ear Infections (Otitis Media)

The clinical evaluation of Cefabac included Randomized Controlled Trials (RCTs) and comparative clinical trials. This research has explored symptom change in pediatric patients (infants 1 month and children). Studies monitored patterns related to symptoms like fever and ear pain, and tracked the measured presence of the targeted bacteria after the typical 7- to 10-day treatment period. What remains uncertain is the long-term characterization of outcomes, and the safety and effectiveness of Cefaclor are not established in infants younger than one month of age.


Evidence for Use in Respiratory Tract Infections

Clinical research has examined Cefabac for upper and lower respiratory tract infections in both adults and children. Research explored short-term changes in outcomes related to systemic or functional imbalance, such as fever and respiratory function, alongside the microbiological assessment of specific respiratory pathogens. A notable limitation documented in regulatory summaries is the limited information establishing the role in the subsequent prevention of rheumatic fever.


Evidence for Use in Urinary Tract and Skin Infections

Cefabac was evaluated in clinical studies for uncomplicated urinary tract infections (UTIs) and certain skin and skin structure infections. The studies also monitored bacteriological outcomes, which were linked to the status of the infection-causing organisms. Data for certain groups remain insufficient, particularly for use in patients with severe renal impairment (severe kidney issues).


What is Still Uncertain About Cefabac

The overall evidence landscape, which covers the studied uses, contains specific areas of uncertainty and research gaps. Regulatory summaries indicate that the safety and effectiveness in treating clinical infections due to certain specific bacterial organisms have not been established in adequate and well-controlled trials. The evidence highlights what is known—and what is still uncertain—emphasizing that study results reflect group patterns and not individual predictions.

Key Studies & References

  1. Cephalosporins: Clinical Use and Safety (A Review)

Frequently Asked Questions (FAQ)

Common questions about Cefabac (FAQ)

Q: How quickly does Cefabac start working?

A: Official regulatory documents indicate that the average peak concentration of Cefabac in the blood is typically achieved quickly, often within mathbf30 to mathbf60 minutes after administration to fasting subjects. This measurement reflects when the drug is most concentrated in the bloodstream, but the time to experience therapeutic effects can vary among individuals.


Q: Does Cefabac cause drowsiness?

A: Regulatory safety summaries have documented drowsiness, which is medically termed mathbfsomnolence, as an uncommon or rare adverse reaction for Cefaclor formulations. This is a factor described in the regulatory profile.


Q: What's the difference between Cefabac and Amoxicillin?

A: Cefabac ( Cefaclor) belongs to the mathbfcephalosporin family of antibiotics, whereas mathbfAmoxicillin belongs to the mathbfpenicillin family. While both are beta-lactam antibiotics, Cefabac is classified as a mathbfsecond-mathbfgeneration cephalosporin, which means it has a distinct chemical structure and antimicrobial coverage profile compared to Amoxicillin.


Q: Is Cefabac safe to use during pregnancy?

A: Official regulatory documents classify Cefaclor as a mathbfPregnancy mathbfCategory mathbfB drug. This classification indicates that animal reproduction studies have generally not shown a risk to the developing fetus, but there are no adequate and well-controlled studies specifically conducted in pregnant women. Use during pregnancy is generally considered only when clearly necessary.


Q: What should I do if I miss a dose of Cefabac?

A: Official documents generally describe that if a dose is missed, it should be taken as soon as it is remembered. If it is near the time for the next dose, the official guidance indicates the missed dose should be skipped. The guidance states that users should not take two doses at the same time.


Q: Are there any common foods to avoid while taking Cefabac?

A: There are mathbfno mathbfspecific mathbffoods mathbflisted for avoidance in the regulatory information. However, taking Cefabac with food may mathbfreduce mathbfand mathbfdelay the peak concentration of the drug in the blood, although the total amount of the drug absorbed remains unchanged.


Q: Are there different strengths of Cefabac available?

A: Yes, regulatory documents list several available strengths for Cefabac. For example, the capsule form is commonly available in mathbf250 mathbfmg and mathbf500 mathbfmg strengths. The oral suspension is also available in different concentrations like mathbf125 mathbfmg/5 mathbfmL and mathbf250 mathbfmg/5 mathbfmL.


Q: Does Cefabac affect birth control pills?

A: The regulatory product information notes a potential interaction concerning mathbfestrogen mathbforal mathbfcontraceptives. The regulatory documentation states that Cefabac mathbfmay mathbfdecrease mathbfthe mathbfdocumented mathbfefficacy of these specific types of birth control medications.


Q: Can children take Cefabac?

A: Yes, Cefabac's safety and effectiveness have been established for use in mathbfpediatric mathbfpatients mathbfone mathbfmonth mathbfof mathbfage mathbfand mathbfolder. However, the drug is mathbfnot mathbfestablished for use in infants younger than mathbfone mathbfmonth mathbfold.


Q: How long do most people take Cefabac for?

A: The typical duration of treatment defined in official labeling is mathbf7 mathbfto mathbf10 mathbfdays. For certain specific infections, such as those caused by beta-haemolytic streptococci, therapy must be continued for a minimum of mathbf10 mathbfdays.


Q: Is Cefabac used for skin infections?

A: Yes, Cefabac is indicated in official documents for the treatment of uncomplicated mathbfskin mathbfand mathbfskin mathbfstructure mathbfinfections. These are infections caused by susceptible organisms like certain types of extitStaphylococcus and extitStreptococcus bacteria.


Q: Does Cefabac affect blood sugar levels?

A: Official information mentions a potential mathbfinteraction mathbfwith mathbflaboratory mathbftests. Cefaclor mathbfmay mathbfcause mathbfa mathbffalse-mathbfpositive mathbfreaction mathbffor mathbfglucose mathbfin mathbfthe mathbfurine when specific copper reduction methods are used.


Q: Is Cefabac a broad-spectrum antibiotic?

A: Cefabac is a mathbfsecond-mathbfgeneration mathbfcephalosporin antibiotic. This classification generally gives it a mathbfbroader mathbfspectrum of activity against certain mathbfGram-mathbfnegative bacteria compared to older, first-generation cephalosporins, in addition to its Gram-positive coverage.


Q: What happens if you stop taking Cefabac early?

A: Patient information from regulatory labels explains that failing to complete the full course of therapy may mathbfdecrease mathbfthe mathbfeffectiveness of the treatment. The information also notes that this action may mathbfincrease mathbfthe mathbfrisk of bacteria developing resistance.


Q: Does Cefabac interact with blood thinners?

A: Yes, regulatory documents report an interaction with the blood thinner mathbfWarfarin. When taken with Cefabac, the mathbfanticoagulant mathbfeffect of Warfarin mathbfmay mathbfbe mathbfenhanced. This reported interaction may necessitate monitoring of prothrombin time.


Q: Will Cefabac make me feel tired or dizzy?

A: Adverse reaction reports for Cefabac have included mathbfdizziness and mathbfsomnolence (drowsiness) as uncommon or rare central nervous system effects. Additionally, mathbfheadache is listed as a common adverse reaction for some formulations.


Q: Is Cefabac used for ear infections?

A: Yes, Cefabac is indicated for the treatment of mathbfotitis mathbfmedia, which is a middle ear infection. It is used to treat this condition when it is caused by susceptible bacterial organisms.


Q: How does Cefabac work to treat bacteria?

A: Cefabac works by having a mathbfbactericidal mathbfaction, which means it actively kills bacteria. It achieves this by mathbfinhibiting mathbfthe mathbfsynthesis mathbfof mathbfthe mathbfbacterial mathbfcell mathbfwall by binding to specific proteins within the cell.


Q: What are the ingredients (besides the active one) in Cefabac tablets?

A: The active ingredient in Cefabac is Cefaclor. Regulatory documentation lists several mathbfinactive mathbfingredients that may be included in the capsules or tablets to give them form and stability. These can include mathbfmagnesium mathbfstearate, mathbflactose mathbfmonohydrate, and mathbftalc, though the exact components depend on the specific formulation.


Q: How is Cefabac eliminated from the body?

A: Cefabac is mathbfprimarily mathbfeliminated mathbfthrough mathbfthe mathbfkidneys. Pharmacokinetic data shows that a large amount of the drug, approximately mathbf60%-mathbf85%, is mathbfexcreted mathbfunchanged mathbfin mathbfthe mathbfurine within eight hours of administration.


Q: Can Cefabac cause changes in mood or behavior?

A: Rare adverse reactions affecting the central nervous system have been reported for some Cefaclor formulations. These reactions include mathbfnervousness, mathbfagitation, mathbfconfusion, and mathbfhallucinations, as documented in regulatory safety summaries.


Q: Is Cefabac used to prevent infections?

A: Cefabac is primarily indicated for the mathbftreatment of proven or strongly suspected bacterial infections. Official guidance emphasizes that prescribing Cefabac is appropriate for a bacterial infection and not typically for general prevention.


Q: Can Cefabac be taken on an empty stomach?

A: Official administration conditions vary by formulation. mathbfImmediate-mathbfrelease forms of Cefabac mathbfmay mathbfbe mathbftaken mathbfwith mathbfor mathbfwithout mathbffood. However, the mathbfextended-mathbfrelease tablets should generally be taken with a meal or within one hour of eating.

How should Cefabac be stored and disposed of?

How to Store and Dispose of Cefabac?

Regulatory documents define strict, mandatory storage requirements for Cefabac (Cefaclor) that differ based on the form. All forms must be stored in the original, tightly closed container and kept out of the sight and reach of children.

Official Storage and Stability Constraints

Formulation Required Storage Condition Stability/Disposal Rule
Capsules/Tablets Controlled Room Temperature (15 C to 30 C); Protect from excess heat, moisture, and light. No specific in-use limit for tablets or capsules.
Oral Suspension (Mixed) Refrigerated (2 C to 8 C); Do not freeze. Must be thrown away after 14 days of mixing.

Any unused or expired liquid suspension must be discarded after 14 days following reconstitution, and disposal of all product waste must adhere to local governmental requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefabac found in:

A-Z Index: